Endocrine Tumor Genetics

The Endocrine Tumor Genetics Program helps to identify and provide comprehensive, coordinated medical care for families that have a hereditary risk for endocrine tumors. Our program is a collaboration between the Center for Cancer Risk Assessment (CCRA) and Thyroid Associates at Massachusetts General Hospital, and includes specialists in both endocrinology and genetics. Patients with pathogenic variants in hereditary endocrine tumor genes are managed comprehensively with our team of endocrinologists and genetic counselors. We also provide risk assessment for patients interested in an evaluation for hereditary endocrine tumors. During the initial genetics consultation, family history is carefully reviewed. If your personal or family history suggests a possible genetic risk, we will discuss the option of genetic.

    Related Conference of Endocrine Tumor Genetics

    March 26-27, 2026

    7th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands
    May 14-15, 2026

    7th World Summit on Diabetes

    Rome, Italy
    May 18-19, 2026

    57th Annual Congress on Endocrinology and Diabetes Research

    Aix-en-Provence, France
    June 22-23, 2026

    16th World Congress on Endocrinology and Diabetes

    Paris, France
    August 17-18, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada
    September 29-30, 2026

    22nd World Congress on Endocrinology & Diabetes

    Paris, France

    Endocrine Tumor Genetics Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in